Incyte
Incyte

Incyte

Biotechnology
WebsiteInvestor RelationsSEC
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

$24.4B

Market Cap • 11/6/2026

1991

(35 years)

Founded

1993

(33 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

S&P500 Participant

Index Composite • 2026

Valuation

P/B

4,3

P/S

4,1

P/EBITDA

33,6

P/OCF

32,7

P/FCF

35,6

P/E

63,6

BVPS

27,7

EPS

2

Market Cap

Market Cap

24,4B

EV

20,6B

EV/Revenue

3,4

EV/EBITDA

28,4

EV/EBIT

32,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1,3%

Total Yield

-1,3%

Payout

0%

Retained Earnings

317,9M

Profitability

Gross Margin

92,7%

EBITDA Margin

12,1%

EBIT Margin

10,4%

Net Margin

6,7%

D&A/EBITDA

0%

R&D/Revenue

57,2%

Capex/Revenue

1%

Capex/D&A

61,1%

Capex/OCF

8,1%

SBC/OCF

35,3%

% PPE

10%

% Goodwill

1,8%

ROE

7,8%

ROIC

15,6%

Growth

CAGR Revenue 5Y

15,6%

CAGR Op. Income 5Y

-0,4%

CAGR Net Income 5Y

-5,5%

CAGR EPS 5Y

-4,8%

CAGR OCF 5Y

0,1%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,8

Quick Ratio

3,5

Interest Coverage

26797%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium